American Heart Journal
Volume 142, Issue 2 , Page E1 , August 2001

Inhibition by combined therapy with ticlopidine and aspirin of enhanced platelet aggregation during physical exercise in patients with coronary artery disease

Received 28 September 2000 ,Accepted 13 April 2001.

References 

  1. Tofler GH. Triggering and the pathophysiology of acute coronary syndromes. Am Heart J. 1997;134(Suppl):S55–S61
  2. Williams PT. Physical activity and public health. JAMA. 1995;274:533–534
  3. Siscovick DS, Weiss NS, Fletcher RH, et al.  The incidence of primary cardiac arrest during vigorous exercise. N Engl J Med. 1984;311:874–877
  4. Mittleman MA, Maclure M, Tofler GH, et al.  Triggering of acute myocardial infarction by heavy physical exertion: protection against triggering by regular exertion. N Engl J Med. 1993;329:1677–1683
  5. Thompson PD, Stern MP, Williams P, et al.  Deaths during jogging or running: a study of 18 cases. JAMA. 1979;242:1265–1267
  6. Mehta J, Mehta P. Comparison of platelet function during exercise in normal subjects and coronary artery disease patients: potential role of platelet activation in myocardial ischemia. Am Heart J. 1982;103:49–53
  7. Sinzinger H, Virgolini I. Effects of exercise on parameters of blood coagulation, platelet function and the prostaglandin system. Sports Med. 1988;6:238–245
  8. Kestin AS, Ellis PA, Barnard MR, et al.  Effect of strenuous exercise on platelet activation state and reactivity. Circulation. 1993;88:1502–1511
  9. Wang JS, Jen CJ, Kung HC, et al.  Different effects of strenuous exercise and moderate exercise on platelet function in men. Circulation. 1994;90:2877–2885
  10. Goto S, Handa S. Coronary thrombosis: effect of blood flow on the mechanism of thrombus formation. Jpn Heart J. 1998;34:579–596
  11. Ruggeri ZM. Old concepts and new developments in the study of platelet aggregation. J Clin Invest. 2000;105:699–701
  12. Ikeda Y, Handa M, Kawano K, et al.  The role of von Willebrand factor and fibrinogen in platelet aggregation under varying shear stress. J Clin Invest. 1991;87:1234–1240
  13. Kroll MH, Hellums JD, MacIntire LV, et al.  Platelets and shear stress. Blood. 1996;88:1525–1541
  14. Antiplatelet Trialists’ Collaboration . Collaborative overview of randomized trials of antiplatelet therapy, I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ. 1994;308:81–106
  15. Schussheim AE, Fuster V. Thrombosis, antithrombotic agents, and the antithrombotic approach in cardiac disease. Prog Cardiovasc Dis. 1997;40:205–238
  16. Tanigawa T, Nishikawa M, Kitai T, et al.  Increased platelet aggregability in response to shear stress in acute myocardial infarction and its inhibition by combined therapy with aspirin and cilostazol after coronary intervention. Am J Cardiol. 2000;85:1054–1059
  17. Goto S, Sakai H, Goto M, et al.  Enhanced shear-induced platelet aggregation in acute myocardial infarction. Circulation. 1999;99:608–613
  18. Takuue J, Hayashi J, Hata Y, et al.  Enhanced platelet aggregability under high shear stress after treadmill exercise in patients with effort angina. Thromb Haemost. 1996;75:833–837
  19. Tofler GH, Brezinski D, Schafer AI, et al.  Concurrent morning increase in platelet aggregability and the risk of myocardial infarction and sudden cardiac death. N Engl J Med. 1987;316:1514–1518
  20. Nishikawa M, Hidaka H. Role of calmodulin in platelet aggregation. J Clin Invest. 1982;69:1348–1355
  21. Tsuruta M, Utsunomiya T, Yoshida K, et al.  Effect of ticlopidine on exercise-induced platelet aggregation and exercise tolerance time in patients with ischemic heart disease. J Cardiovasc Pharmacol. 1999;33:659–664
  22. Siess W, Loren R, Roth P, et al.  Plasma catecholamines, platelet aggregation and associated thromboxane formation after physical exercise, smoking or norepinephrine infusion. Circulation. 1982;66:44–48
  23. Hendra TJ, Oughton J, Smith CCT, et al.  Exercise-induced changes in platelet aggregation: a comparison of whole blood and platelet rich plasma techniques. Thromb Res. 1988;52:443–451
  24. Uchiyama S, Yamazaki M, Maruyama S, et al.  Shear-induced platelet aggregation in cerebral ischemia. Stroke. 1994;25:1547–1551
  25. Cattaneo M, Lombardi R, Bettega D, et al.  Shear-induced platelet aggregation is potentiated by desmopressin and inhibited by ticlopidine. Arterioscler Thromb. 1993;13:393–397
  26. Galbusera M, Zoja C, Donadelli R, et al.  Fluid shear stress modulates von Willebrand factor release from human vascular endothelium. Blood. 1997;90:1558–1564
  27. Moake JL, Turner NA, Stathopoulos NA, et al.  Shear-induced platelet aggregation can be mediated by vWF released from platelets, as well as by exogeneous large or unusually large vWF multimers, required adenosine diphosphate, and is resistant to aspirin. Blood. 1988;71:1366–1374
  28. Schrör K. Antiplatelet drugs. a comparative review. Drugs. 1995;50:7–28
  29. Kvernmo HD, Østerud B. The effect of physical conditioning suggests adaptation in procoagulant and fibrinolytic potential. Thromb Res. 1997;87:559–569
  30. Koenig W, Ernst E. Exercise and thrombosis. Coron Artery Dis. 2000;11:123–127
  31. Nikfardjam M, Graf S, Beckmann R, et al.  Fibrinolytic response to venous occlusion compared to physical stress test in young patients with coronary artery disease. Thromb Haemost. 1999;82(1 Suppl):80–84
  32. CAPRIE Steering Committee . A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischemic events (CAPRIE). Lancet. 1996;348:1329–1339
  33. Bertrand ME, Rupprecht H-J, Urban P, et al.  Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting: the Clopidogrel Aspirin Stent International Cooperative Study (CLASSICS). Circulation. 2000;102:624–629

☆ Supported in part by grants for research from the Ministry of Education, Science, Technology, Sports, and Culture of Japan and by grants from the Mie Medical Research Foundation.

☆☆ Reprint requests: Masakatsu Nishikawa, MD, 2nd Department of Internal Medicine, Mie University School of Medicine, 2-174 Edobashi, Tsu, Mie 514-8507, Japan. E-mail: nisikawa@clin.medic.mie-u.ac.jp

PII: S0002-8703(01)91534-0

doi: 10.1067/mhj.2001.116485

American Heart Journal
Volume 142, Issue 2 , Page E1 , August 2001

Article Tools

* Image Usage & Resolution